Welcome to our dedicated page for Evolus news (Ticker: EOLS), a resource for investors and traders seeking the latest updates and insights on Evolus stock.
Evolus, Inc. (NASDAQ: EOLS) is a performance beauty company focused on aesthetic injectables, and its news flow reflects both commercial execution and product development in this space. Company press releases highlight its mission to build an aesthetic portfolio anchored by Jeuveau, a neurotoxin dedicated exclusively to aesthetics, and Evolysse, a collection of injectable hyaluronic acid (HA) gels. Readers following EOLS news can see how these product families shape the company’s growth in the self-pay aesthetic market.
News updates frequently cover financial results and guidance, including quarterly net revenue, product mix between global Jeuveau revenue and Evolysse revenue, and commentary on non-GAAP operating income. Management discussions in these releases describe trends in customer accounts, reorder rates, and loyalty program participation through the Evolus Rewards consumer program, providing insight into adoption of the company’s injectables.
Evolus news also features clinical and regulatory milestones for its HA filler portfolio. For example, the company has reported positive topline data from a pivotal study of Evolysse Sculpt, an injectable HA gel product designed to restore mid-face volume, and described the submission of a Premarket Approval application to the U.S. Food and Drug Administration. Additional updates discuss the U.S. commercialization of Evolysse Form and Evolysse Smooth and anticipated timelines for Evolysse Sculpt and Estyme-branded products in Europe.
Investors and industry observers can also find corporate and governance updates in Evolus news, such as executive appointments, inducement equity grants under Nasdaq Listing Rule 5635(c)(4), and participation in healthcare and investor conferences. Together, these items provide a view of how Evolus manages its leadership, capital incentives, and investor outreach as it pursues its performance beauty strategy. Bookmarking the EOLS news page allows users to monitor ongoing developments in financial performance, product launches, clinical data, and corporate actions related to Evolus’ aesthetic injectable business.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Evolus reported Q4 2022 net revenue of $43.6 million, a 26% increase from Q4 2021, and a full-year revenue of $148.6 million, up 49% year-over-year. The company reaffirmed its 2023 revenue guidance of $180-$190 million, anticipating growth exceeding the overall U.S. aesthetic neurotoxin market. Jeuveau® remains the fastest-growing neurotoxin in the U.S. with over 700 new customer accounts added in Q4 2022, bringing total accounts to above 9,500. The company aims for a positive non-GAAP operating income in Q4 2023 without requiring additional capital.
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company, will participate in the Barclays Global Healthcare Conference on March 14, 2023, from 2:35 to 3:00 PM ET in Miami Beach, Florida. The event will be accessible via an audio webcast on Evolus' investor relations page at www.evolus.com, with a replay available for 90 days post-event. Evolus aims to revolutionize the aesthetic neurotoxin market with its flagship product, Jeuveau®, a neurotoxin solely dedicated to aesthetics, produced using Hi-Pure™ technology. More details can be found on their official website.
Evolus, Inc. (NASDAQ: EOLS) has launched Nuceiva® in Germany and Austria, marking a significant expansion in the European aesthetic toxin market. This product, approved by the European Commission, targets moderate to severe vertical lines between the eyebrows in adults under 65. The company is partnering with Novvia for distribution in these regions and anticipates entering more European countries and Australia in 2023. The launch follows extensive clinical trials demonstrating the effectiveness of Nuceiva® compared to Botox®. Evolus aims to enhance its market presence and meet growing consumer demand for aesthetic treatments.
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company, will announce its fourth quarter and year-end 2022 financial results on March 8, 2023, after U.S. markets close. Following this announcement, management will host a conference call and live webcast at 4:30 p.m. ET to discuss the results, including a Q&A session. Participants can join the call via phone or the company's Investor Relations website. A replay of the call will be available afterward. Evolus focuses on the aesthetic neurotoxin market and aims to evolve beauty consumer experiences with innovative products like Jeuveau®, its flagship offering.